- Home
- LCTX vs FLL Comparison
LCTX vs FLL Comparison
Compare LCTX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FLL
- Stock Information
- Founded
- LCTX 1990
- FLL 1987
- Country
- LCTX United States
- FLL United States
- Employees
- LCTX N/A
- FLL N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FLL Hotels/Resorts
- Sector
- LCTX Health Care
- FLL Consumer Discretionary
- Exchange
- LCTX Nasdaq
- FLL Nasdaq
- Market Cap
- LCTX 165.6M
- FLL 170.4M
- IPO Year
- LCTX N/A
- FLL 1993
- Fundamental
- Price
- LCTX $0.88
- FLL $4.93
- Analyst Decision
- LCTX Strong Buy
- FLL Buy
- Analyst Count
- LCTX 3
- FLL 2
- Target Price
- LCTX $5.67
- FLL $6.50
- AVG Volume (30 Days)
- LCTX 416.6K
- FLL 68.3K
- Earning Date
- LCTX 08-08-2024
- FLL 08-06-2024
- Dividend Yield
- LCTX N/A
- FLL N/A
- EPS Growth
- LCTX N/A
- FLL N/A
- EPS
- LCTX N/A
- FLL N/A
- Revenue
- LCTX $6,186,000.00
- FLL $274,988,000.00
- Revenue This Year
- LCTX N/A
- FLL $26.61
- Revenue Next Year
- LCTX $119.00
- FLL $13.32
- P/E Ratio
- LCTX N/A
- FLL N/A
- Revenue Growth
- LCTX N/A
- FLL 47.08
- 52 Week Low
- LCTX $0.77
- FLL $3.40
- 52 Week High
- LCTX $1.61
- FLL $5.98
- Technical
- Relative Strength Index (RSI)
- LCTX 47.00
- FLL 48.88
- Support Level
- LCTX $0.83
- FLL $4.86
- Resistance Level
- LCTX $0.92
- FLL $5.11
- Average True Range (ATR)
- LCTX 0.06
- FLL 0.17
- MACD
- LCTX 0.00
- FLL 0.01
- Stochastic Oscillator
- LCTX 36.08
- FLL 51.72
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.